258 related articles for article (PubMed ID: 26982318)
1. Mineralocorticoid Antagonists in the Treatment of Central Serous Chorioretinopathy: A Comparative Analysis.
Kapoor KG; Wagner AL
Ophthalmic Res; 2016; 56(1):17-22. PubMed ID: 26982318
[TBL] [Abstract][Full Text] [Related]
2. Clinical experience with eplerenone to treat chronic central serous chorioretinopathy.
Cakir B; Fischer F; Ehlken C; Bühler A; Stahl A; Schlunck G; Böhringer D; Agostini H; Lange C
Graefes Arch Clin Exp Ophthalmol; 2016 Nov; 254(11):2151-2157. PubMed ID: 27145785
[TBL] [Abstract][Full Text] [Related]
3. Comparison of two mineralcorticosteroids receptor antagonists for the treatment of central serous chorioretinopathy.
Pichi F; Carrai P; Ciardella A; Behar-Cohen F; Nucci P;
Int Ophthalmol; 2017 Oct; 37(5):1115-1125. PubMed ID: 27757733
[TBL] [Abstract][Full Text] [Related]
4. Long-term results and recurrence rates after spironolactone treatment in non-resolving central serous chorio-retinopathy (CSCR).
Herold TR; Rist K; Priglinger SG; Ulbig MW; Wolf A
Graefes Arch Clin Exp Ophthalmol; 2017 Feb; 255(2):221-229. PubMed ID: 27475933
[TBL] [Abstract][Full Text] [Related]
5. Eplerenone for chronic central serous chorioretinopathy-a randomized controlled prospective study.
Schwartz R; Habot-Wilner Z; Martinez MR; Nutman A; Goldenberg D; Cohen S; Shulman S; Guzner-Gur H; Loewenstein A; Goldstein M
Acta Ophthalmol; 2017 Nov; 95(7):e610-e618. PubMed ID: 28653813
[TBL] [Abstract][Full Text] [Related]
6. Mineralocorticoid receptor antagonism in the treatment of chronic central serous chorioretinopathy: a pilot study.
Bousquet E; Beydoun T; Zhao M; Hassan L; Offret O; Behar-Cohen F
Retina; 2013; 33(10):2096-102. PubMed ID: 23719402
[TBL] [Abstract][Full Text] [Related]
7. MINERALOCORTICOID RECEPTOR ANTAGONIST TREATMENT IN BILATERAL CHRONIC CENTRAL SEROUS CHORIORETINOPATHY: A COMPARATIVE STUDY OF EXUDATIVE AND NONEXUDATIVE FELLOW EYES.
Gergely R; Kovács I; Schneider M; Resch M; Papp A; Récsán Z; Nagy ZZ; Ecsedy M
Retina; 2017 Jun; 37(6):1084-1091. PubMed ID: 27627749
[TBL] [Abstract][Full Text] [Related]
8. The Effect of Eplerenone in Chronic Central Serous Chorioretinopathy Refractory to Photodynamic Therapy.
Karagiannis D; Parikakis E; Kontomichos L; Batsos G; Chatziralli I
Semin Ophthalmol; 2019; 34(6):436-441. PubMed ID: 31309849
[No Abstract] [Full Text] [Related]
9. Multimodal retinal imaging in central serous chorioretinopathy treated with oral eplerenone or photodynamic therapy.
Rabiolo A; Zucchiatti I; Marchese A; Baldin G; Sacconi R; Montorio D; Cicinelli MV; Querques L; Bandello F; Querques G;
Eye (Lond); 2018 Jan; 32(1):55-66. PubMed ID: 29265111
[TBL] [Abstract][Full Text] [Related]
10. COMPARISON OF SHORT-TERM EFFICACY BETWEEN ORAL SPIRONOLACTONE TREATMENT AND PHOTODYNAMIC THERAPY FOR THE TREATMENT OF NONRESOLVING CENTRAL SEROUS CHORIORETINOPATHY.
Lee JH; Lee SC; Kim H; Lee CS
Retina; 2019 Jan; 39(1):127-133. PubMed ID: 29095358
[TBL] [Abstract][Full Text] [Related]
11. [Eplerenone treatment in chronic central serous chorioretinopathy].
Sampo M; Soler V; Gascon P; Ho Wang Yin G; Hoffart L; Denis D; Matonti F
J Fr Ophtalmol; 2016 Jun; 39(6):535-42. PubMed ID: 27230892
[TBL] [Abstract][Full Text] [Related]
12. Mineralocorticoid Receptor Antagonists in Central Serous Chorioretinopathy: A Meta-Analysis of Randomized Controlled Trials.
Wang SK; Sun P; Tandias RM; Seto BK; Arroyo JG
Ophthalmol Retina; 2019 Feb; 3(2):154-160. PubMed ID: 31014765
[TBL] [Abstract][Full Text] [Related]
13. Two-year follow-up of mineralocorticoid receptor antagonists for chronic central serous chorioretinopathy.
Zola M; Daruich A; Matet A; Mantel I; Behar-Cohen F
Br J Ophthalmol; 2019 Aug; 103(8):1184-1189. PubMed ID: 30355720
[TBL] [Abstract][Full Text] [Related]
14. Oral eplerenone for treatment of chronic central serous chorioretinopathy: a case series.
Salz DA; Pitcher JD; Hsu J; Regillo CD; Fineman MS; Elliott KS; Vander JF; Fischer DH; Spirn MJ
Ophthalmic Surg Lasers Imaging Retina; 2015 Apr; 46(4):439-44. PubMed ID: 25970864
[TBL] [Abstract][Full Text] [Related]
15. CENTRAL SEROUS CHORIORETINOPATHY TREATED WITH MINERALOCORTICOID ANTAGONISTS: A ONE-YEAR PILOT STUDY.
Ghadiali Q; Jung JJ; Yu S; Patel SN; Yannuzzi LA
Retina; 2016 Mar; 36(3):611-8. PubMed ID: 26405766
[TBL] [Abstract][Full Text] [Related]
16. The use of eplerenone in therapy-resistant chronic central serous chorioretinopathy.
Breukink MB; den Hollander AI; Keunen JE; Boon CJ; Hoyng CB
Acta Ophthalmol; 2014 Sep; 92(6):e488-90. PubMed ID: 24698599
[No Abstract] [Full Text] [Related]
17. Oral Mineralocorticoid-Receptor Antagonists: Choroidal Parameters Changes Using OCT in Central Serous Chorioretinopathy.
Faghihi H; Mohammadzadeh V; Nabavi A; Faghihi S; Kadivar S; Ghassemi F
Ophthalmic Surg Lasers Imaging Retina; 2019 Nov; 50(11):726-733. PubMed ID: 31755972
[TBL] [Abstract][Full Text] [Related]
18. Systemic Mineralocorticoid Antagonists in the Treatment of Central Serous Chorioretinopathy.
Yang D; Eliott D
Semin Ophthalmol; 2017; 32(1):36-42. PubMed ID: 27929707
[TBL] [Abstract][Full Text] [Related]
19. A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROL PILOT STUDY OF EPLERENONE FOR THE TREATMENT OF CENTRAL SEROUS CHORIORETINOPATHY (ECSELSIOR).
Rahimy E; Pitcher JD; Hsu J; Adam MK; Shahlaee A; Samara WA; Vander JF; Kaiser RS; Chiang A; Spirn MJ; Fineman MS
Retina; 2018 May; 38(5):962-969. PubMed ID: 28426624
[TBL] [Abstract][Full Text] [Related]
20. Clinical efficacy of eplerenone versus placebo for central serous chorioretinopathy: study protocol for the VICI randomised controlled trial.
Willcox A; Culliford L; Ellis L; Rogers CA; Cree A; Chakravarthy U; Ennis S; Behar-Cohen F; Reeves BC; Sivaprasad S; Lotery A
Eye (Lond); 2019 Feb; 33(2):295-303. PubMed ID: 30194380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]